ClinicalTrials.gg
CompletedNCT02283853CONNECTUpdated May 19, 2026Results posted

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

A Phase 3 interventional study of dimethyl fumarate and Interferon β-1a in Relapsing-Remitting Multiple Sclerosis, sponsored by Biogen. Completed at 62 sites in 18 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
156
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Dimethyl Fumarate · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
9th of 22
156 · median 61
Started
2014
with 2 others
Phase 3
10 of 22
none open now
Registered
10th of 22
by date
Lead sponsor
18 of 22
Biogen

Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, this one is the 9th largest by enrollment, is one of 3 that started in 2014, is one of 10 in phase 3, and was the 10th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About Dimethyl Fumarate

Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

The main objectives of Part 1 are as follows: To evaluate the safety, tolerability, and efficacy of BG00012 in pediatric participants with RRMS, as compared with a disease-modifying treatment and to assess health outcomes and evolution of disability. The primary objective of Part 2 is to evaluate the long-term safety of BG00012 in participants who completed Week 96 in Part 1 of Study 109MS306. The secondary objective of Part 2 is to describe the long-term MS outcomes of BG00012 in participants who completed Week 96 in Part 1 of Study 109MS306.

03

Conditions studied

  • Relapsing-Remitting Multiple Sclerosis

Keywords

  • Pediatrics
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Males and females aged from 10 to less than 18 years old at the time of or assent.
  • Must have a body weight of ≥30 kg.
  • Must have a diagnosis of RRMS (consensus definition for pediatric RRMS [Krupp 2013]).
  • Must be ambulatory with a baseline EDSS score between 0 and 5.5, inclusive.
  • Must have experienced at least 1 of the following 3 conditions: a) at least 1 relapse within the last 12 months prior to Day 1 with a prior brain MRI demonstrating lesions consistent with MS; b) at least 2 relapses within the last 24 months prior to Day 1, with a prior brain MRI demonstrating lesions consistent with MS; c) evidence of Gd-enhancing lesions of the brain on an MRI performed within the 6 weeks prior to Day 1.
  • Must be neurologically stable, with no evidence of relapse within 50 days prior to Day 1 and no evidence of treatment within 30 days prior to Day 1.
  • Participants of who are sexually active must be willing to practice effective during the study and be willing and able to continue contraception for at least 30 days after their final dose of study treatment.

Key Exclusion Criteria:

  • Primary progressive, secondary progressive, or progressive relapsing MS (as defined by [Lublin and Reingold 1996]). These conditions require the presence of continuous clinical disease worsening over a period of at least 3 months. Participants with these conditions may also have superimposed relapses but are distinguished from relapsing-remitting participants by the lack of clinically stable periods or clinical improvement.
  • Disorders mimicking MS, such as other demyelinating disorders (e.g., acute disseminated encephalomyelitis), systemic disorders (e.g., Sjögren disease, lupus erythematosus), metabolic disorders (e.g., dystrophies), and infectious disorders.
  • History of premalignant or malignant disease. Participants with basal cell carcinoma that has been completely excised prior to screening will remain eligible.
  • History of severe allergic or anaphylactic reactions, or known drug to DMF, fumaric acid esters, or interferon beta-1a (IFN Beta-1a).
  • History of abnormal laboratory results indicative of any significant endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, renal, and/or any other major disease that would preclude participation in a clinical study.
  • History of cardiovascular, pulmonary, GI, dermatologic, growth, developmental, psychiatric (including depression), neurologic (other than MS), and/or other major disease that would preclude participation in a clinical study.
  • History of .
  • An MS relapse that has occurred within 50 days prior to Day 1 AND/OR the participant has not stabilized from a previous relapse prior to Day 1.
  • Other unspecified reasons that, in the opinion of the Investigator or Biogen Idec, make the participant unsuitable for enrollment.

NOTE: Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    BG00012

    Participants will receive the recommended dose of 240 mg orally, twice a day

    Drug: dimethyl fumarate

  • Active comparator
    IFN β-1a (Avonex)

    Participants will receive the recommended dose of 30 μg (weekly)

    Drug: Interferon β-1a

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Proportion of Participants Free of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans

    Participants who were free of new or newly enlarging T2 hyperintense lesions were assessed on Brain MRI scans.

    Time frame: At Week 96

  2. Part 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE was any untoward medical occurrence that at any dose resulted in death, in the view of the Investigator, placed the participant at immediate risk of death, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a birth defect. TEAEs were defined as AEs occurring or worsening after beginning study treatment (after the first dose).

    Time frame: From Week 96 up to last follow-up visit (up to Week 340)

  3. Part 2: Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE was any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: From Week 96 up to last follow-up visit (up to Week 340)

Secondary outcomes

  1. Part 1: Number of New or Newly Enlarged T2 Hyperintense Lesions on Brain MRI Scans

    The number of new or newly enlarging T2 hyperintense lesions that developed in each participant was assessed on Brain MRI scans.

    Time frame: At Weeks 24 and Week 96

  2. Part 1: Proportion of Participants Free of New or Newly Enlarging T2 Hyperintense Lesions on Brain MRI Scans

    Participants who were free of new or newly enlarging T2 hyperintense lesions were assessed on Brain MRI scans.

    Time frame: At Weeks 24 and 48

  3. Part 1: Proportion of Participants Free of New MRI Activity as Measured by Brain MRI Scans

    Participants free of Gd-enhancing MRI lesions and new or newly enlarging T2 MRI lesions were assessed on Brain MRI Scans.

    Time frame: At Weeks 24, 48, and 96

  4. Part 1: Time to First Relapse

    Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the examining neurologist. The time to first relapse was defined as the time from the first dose in Part 1 up to the first relapse. Time to First Relapse was estimated by Kaplan-Meier method.

    Time frame: Up to Week 96

  5. Part 1: Proportion of Relapse-Free Participants

    Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the examining neurologist. The proportion of relapse-free participants was estimated using the Kaplan-Meier method.

    Time frame: Up to Week 96

  6. Part 1: Annualized Relapse Rate (ARR)

    ARR is calculated as the total number of relapses that occurred during the study divided by the total number of participant-years. ARR was analyzed using negative binomial regression model.

    Time frame: At Weeks 48 and 96

  7. Part 1: Number of Participants With TEAEs and TESAEs

    An AE was any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE was any untoward medical occurrence that at any dose resulted in death, in the view of the Investigator, placed the participant at immediate risk of death, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a birth defect. TEAEs were defined as AEs occurring or worsening after beginning study treatment (after the first dose).

    Time frame: From Day 1 up to Week 96

  8. Part 1: Change From Baseline in Vital Signs (Temperature)

    Negative change from baseline indicated reduction in temperature.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84 and 96

  9. Part 1: Change From Baseline in Vital Signs (Pulse Rate)

    Negative change from baseline indicated reduction in pulse rate.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84 and 96

  10. Part 1: Change From Baseline in Vital Signs (Blood Pressure)

    Negative change from baseline indicated reduction in blood pressure.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84 and 96

  11. Part 1: Change From Baseline in Vital Signs (Respiratory Rate)

    Negative change from baseline indicated reduction in respiratory rate.

    Time frame: Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84 and 96

  12. Part 1: Number of Participants With Shifts From Baseline in Electrocardiograms (ECG) Abnormalities

    Clinical significance of abnormalities in ECG was determined based on the investigator's discretion. Shift to abnormal indicated values that were normal or unknown at baseline and shifted to abnormal values post-baseline.

    Time frame: Up to Week 96

  13. Part 1: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Hematology Parameters)

    Hematology parameters included leukocytes, erythrocytes, hemoglobin, hematocrit, platelets, eosinophils, lymphocytes, monocytes and neutrophils. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values. The categories with at least one participant with shift from baseline in these parameters are reported.

    Time frame: Baseline up to Week 96

  14. Part 1: Change From Baseline in Coagulation Parameters [Activated Partial Thromboplastin Time (aPTT)]

    A negative change from baseline indicated a reduction in aPTT.

    Time frame: Baseline, Weeks 24, 48 and 96

  15. Part 1: Change From Baseline in Coagulation Parameters [Prothrombin Time (PT)]

    A negative change from baseline indicated a reduction in PT.

    Time frame: Baseline, Weeks 24, 48 and 96

  16. Part 1: Change From Baseline in Coagulation Parameters [International Normalized Ratio (INR)]

    A negative change from baseline indicated a reduction in clotting time.

    Time frame: Baseline, Weeks 24, 48 and 96

  17. Part 1: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters)

    Parameters included sodium, potassium, chloride, bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, urea nitrogen, creatinine, bicarbonate, calcium, magnesium, phosphate, urate and glucose. These parameters were flagged as low, normal or high relative to parameter's normal range or as unknown if no result was available, by Investigator. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high values postbaseline. Categories with at least one participant with shift from baseline in these parameters are reported.

    Time frame: Baseline up to Week 96

  18. Part 1: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Urinalysis Parameters)

    Urinalysis included assessments of glucose, ketones, occult blood, protein, specific gravity. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available, by the Investigator. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline. The categories with at least one participant with shift from baseline in these parameters are reported.

    Time frame: Baseline up to Week 96

  19. Part 1: Fatigue Score Measured by the Pediatric Quality of Life Inventory (PedsQL) Multidimensional Fatigue Scale

    The PedsQL multidimensional fatigue questionnaire was answered by the participant (self-assessment) and parent. The fatigue scale contains 18 questions in 3 fatigue dimensions: general fatigue, sleep/rest fatigue and cognitive fatigue. Each item was scored on 5-point Likert scale (0=never to 4=almost always). Each individual score was then reversed (subtracted from 4) and linearly transformed as follows: 0=100, 1=75, 2=50, 3=25, 4=0. For each dimension, total score was calculated as the sum of all the items/number of items answered. A higher total score indicated fewer problems.

    Time frame: Up to Week 96

  20. Part 1: Quality of Life (QOL) as Measured by the PedsQL

    The PedsQL QOL questionnaire was answered by the participant (self-assessment) and parent. The QoL scale contains 23 questions in 4 dimensions: Physical Functioning, Emotional Fatigue, Social Fatigue and School Fatigue. Each item was scored on 5-point Likert scale (0=never to 4=almost always). Each individual score was then reversed (subtracted from 4) and linearly transformed as follows: 0=100, 1=75, 2=50, 3=25, 4=0. For each dimension, total score was calculated as the sum of all the items/number of items answered. A higher total score indicated better quality of life.

    Time frame: Up to Week 96

  21. Part 1: Change From Baseline in the Expanded Disability Status Scale (EDSS) Score

    The EDSS measures the disability status of participants with multiple sclerosis on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS with higher scores indicating more disability. A negative change from baseline indicated an improvement in the disability.

    Time frame: Baseline, Week 96

  22. Part 2: Annualized Relapse Rate (ARR)

    ARR is calculated as the total number of relapses that occurred during the study divided by the total number of participant-years. ARR was analyzed using negative binomial regression model.

    Time frame: From Baseline (Week 96) up to Week 336

  23. Part 2: Change From Baseline in the Expanded Disability Status Scale (EDSS) Score

    The EDSS measures the disability status of participants with multiple sclerosis on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. A negative change from baseline indicated an improvement in the disability.

    Time frame: Baseline (Week 96), Week 336

  24. Part 2: Change From Baseline in Brief Visuospatial Memory Test - Revised (BVMT-R) Score

    BVMT-R is used to assess learning/memory. In this test, six abstract designs are presented for 10 sec. The display is removed from view, and participants render the stimuli via pencil on paper, manual responses. Each design receives from 0 to 2 points, representing accuracy and location. There are three Learning Trials, and the score is reported as the total number of points earned over the trials. Thus, scores range from 0 to 12 per trial; total score range is 0 to 36 for all three trials. Scores were converted to standardized scores using normative data, ranging from 2-86. The lower the score, the more severe the cognitive impairment while higher scores reflect better visuospatial memory.

    Time frame: Baseline (Week 96), Weeks 144,192, 240, 288 and 336

  25. Part 2: Change From Baseline in Symbol Digit Modalities Test (SDMT) Score

    SDMT is used to assess processing speed. It consists of 9 abstract symbols. Each symbol is paired with a single digit. The participant is provided with a key, showing each symbol digit pair. In addition, the participants are shown several rows of the 9 symbols, which are arranged pseudo-randomly, without the digit. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 seconds. The SDMT score ranges from 0 to 110, where higher scores indicate improvement in cognitive functioning and lower scores indicate worsening.

    Time frame: Baseline (Week 96), Weeks 144,192, 240, 288 and 336

  26. Part 2: Number of Participants With or Without School Progression

    Participants or caregivers were posed the following question: "During the past year, did \[you/the participant\] progress from one \[class/grade-level\] to the next in school?" Responses were recorded as Yes (participant advanced to the next grade) or No (participant did not advance).

    Time frame: At Weeks 144, 192, 240, 288 and 336

  27. Part 2: Change From Baseline in Vital Signs (Temperature)

    Negative change from baseline indicated reduction in temperature.

    Time frame: Baseline (Week 96), Weeks 120,144, 168, 192, 216, 240, 264, 288, 312, 336, and 340

  28. Part 2: Change From Baseline in Vital Signs (Pulse Rate)

    Negative change from baseline indicated reduction in pulse rate.

    Time frame: Baseline (Week 96), Weeks 120,144, 168, 192, 216, 240, 264, 288, 312, 336, and 340

  29. Part 2: Change From Baseline in Vital Signs (Blood Pressure)

    Negative change from baseline indicated reduction in blood pressure.

    Time frame: Baseline (Week 96), Weeks 120,144, 168, 192, 216, 240, 264, 288, 312, 336, and 340

  30. Part 2: Change From Baseline in Vital Signs (Respiratory Rate)

    Negative change from baseline indicated reduction in respiratory rate.

    Time frame: Baseline (Week 96), Weeks 120,144, 168, 192, 216, 240, 264, 288, 312, 336, and 340

  31. Part 2: Number of Participants With Shifts From Baseline in ECG Abnormalities

    Clinical significance of abnormalities in ECG was determined based on the investigator's discretion. Shift to abnormal indicated values that were normal or unknown at baseline and shifted to abnormal values post-baseline.

    Time frame: From Baseline (Week 96) to Week 336

  32. Part 2: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Hematology Parameters)

    Hematology parameters included leukocytes, erythrocytes, hemoglobin, hematocrit, platelets, eosinophils, lymphocytes, monocytes and neutrophils. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values. The categories with at least one participant with shift from baseline in these parameters are reported.

    Time frame: Baseline (Week 96) up to Week 340

  33. Part 2: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters)

    Parameters included potassium, bilirubin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, urea nitrogen, creatinine, bicarbonate, calcium, magnesium, phosphate, urate and glucose. These parameters were flagged as low, normal or high relative to parameter's normal range or as unknown if no result was available, by Investigator. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high values postbaseline. Categories with at least one participant with shift from baseline in these parameters are reported.

    Time frame: Baseline (Week 96) up to Week 340

  34. Part 2: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Urinalysis Parameters)

    Urinalysis included assessments of erythrocytes, leukocytes and specific gravity. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available, by the Investigator. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline. The categories with at least one participant with shift from baseline in these parameters are reported.

    Time frame: Baseline up to Week 340

  35. Part 2: Change From Baseline in Height

    Time frame: Baseline (Week 96), Weeks 120,144, 168, 192, 216, 240, 264, 288, 312, 336, and 340

  36. Part 2: Change From Baseline in Weight

    Time frame: Baseline (Week 96), Weeks 120,144, 168, 192, 216, 240, 264, 288, 312, 336, and 340

  37. Part 2: Change From Baseline in Bone Age

    Bone age was tested until the participant reached a bone age of 16 years.

    Time frame: Baseline (Week 96), Weeks 144, 192 and 240

  38. Part 2: Number of Male Participants by Tanner Stage Assessment

    Tanner pubertal staging in males was assessed for testes and scrotum development and pubic hair growth, progressing from stage 1 (prepubertal) to stage 5 (adult). Assessments ended when bone age reached ≥16 years. Testes and scrotum stages were: 1-prepubertal; 2-enlargement of testes, scrotum reddens, texture change; 3-Enlargement of penis, further growth of testes; 4-Increased size of penis with growth in breadth and development of glans; testes and scrotum larger, scrotum skin darker; 5-adult genitalia. Pubic hair stages were: 1-prepubertal; 2-Sparse growth of long, slightly pigmented hair, straight or curled; 3-Darker, coarser and more curled hair, spreading sparsely over junction of pubes; 4-Hair adult in type, but covering smaller area than in adult; no spread to medial surface of thighs; 5-Adult in type and quantity, with horizontal distribution.

    Time frame: At Weeks 96, 144, 192, 240, 288 and 336

  39. Part 2: Number of Female Participants by Tanner Stage Assessment

    Tanner pubertal staging in females was assessed for breast development and pubic hair growth, progressing from stage 1 (prepubertal) to stage 5 (adult). Assessments ended when bone age reached ≥16 years or the participant was post-menarche. Breast development stages: 1-prepubertal; 2-breast bud stage with elevation of breast and papilla; enlargement of areola, 3-further enlargement of breast and areola; no separation of their contour; 4-areola and papilla form secondary mound above level of breast; 5-mature stage: projection of papilla only, related to recession of areola. Pubic hair stages: 1-prepubertal (can see velus hair similar to abdominal wall); 2-sparse growth of long, slightly pigmented hair, straight or curled, mainly on labia; 3-Darker, coarser and more curled hair, spreading sparsely over junction of pubes; 4-hair adult in type, but covering smaller area than in adult; no spread to medial surface of thighs; 5-adult in type and quantity, with horizontal distribution.

    Time frame: At Weeks 96, 144, 192, 240, 288 and 336

07

Results

Posted May 19, 2026

Participant flow

Participants took part in the study at multiple investigative sites from 28 August 2014 to 08 July 2025.

Part 1 (Day 1 to Week 96)
Participant flow — Part 1 (Day 1 to Week 96)
MilestonePart 1: BG00012Part 1: Interferon β-1aPart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Started797700
Treated787200
Completed624200
Not completed173500
Withdrew: Randomized not dosed1500
Withdrew: Adverse event5800
Withdrew: Consent withdrawn41100
Withdrew: Investigator decision4900
Withdrew: Reason not specified3200
Part 2 (Week 96 to Week 340)
Participant flow — Part 2 (Week 96 to Week 340)
MilestonePart 1: BG00012Part 1: Interferon β-1aPart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Started005735
Completed001620
Not completed004115
Withdrew: Adverse event0032
Withdrew: Lost to follow-up0031
Withdrew: Withdrawal by subject0085
Withdrew: Physician decision00206
Withdrew: Reason not specified0071

Outcome measures

PrimaryPart 1: Proportion of Participants Free of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans

Participants who were free of new or newly enlarging T2 hyperintense lesions were assessed on Brain MRI scans.

Time frame:
At Week 96
Reported as:
Number · proportion of participants
Part 1: Proportion of Participants Free of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans
proportion of participantsPart 1: BG00012Part 1: Interferon β-1a
Part 1: Proportion of Participants Free of New or Newly Enlarging T2 Hyperintense Lesions on Brain Magnetic Resonance Imaging (MRI) Scans0.161 (0.080 to 0.277)0.049 (0.006 to 0.165)
PrimaryPart 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE was any untoward medical occurrence that at any dose resulted in death, in the view of the Investigator, placed the participant at immediate risk of death, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a birth defect. TEAEs were defined as AEs occurring or worsening after beginning study treatment (after the first dose).

Time frame:
From Week 96 up to last follow-up visit (up to Week 340)
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
ParticipantsPart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
TEAEs4931
TESAEs82
PrimaryPart 2: Number of Participants Who Discontinued Study Treatment Due to an AE

An AE was any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

Time frame:
From Week 96 up to last follow-up visit (up to Week 340)
Reported as:
Count of participants · Participants
Part 2: Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsPart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Part 2: Number of Participants Who Discontinued Study Treatment Due to an AE21
SecondaryPart 1: Number of New or Newly Enlarged T2 Hyperintense Lesions on Brain MRI Scans

The number of new or newly enlarging T2 hyperintense lesions that developed in each participant was assessed on Brain MRI scans.

Time frame:
At Weeks 24 and Week 96
Reported as:
Mean · number of lesions
Part 1: Number of New or Newly Enlarged T2 Hyperintense Lesions on Brain MRI Scans
number of lesionsPart 1: BG00012Part 1: Interferon β-1a
Week 2410.0 ± 14.6111.9 ± 20.16
Week 9619.4 ± 35.7932.1 ± 67.16
Statistical analysis
  • Part 1: BG00012 vs Part 1: Interferon β-1a · Negative binomial regression model · p = =0.1766 · Lesion mean ratio: 0.75 · 95% CI 0.50 to 1.14Estimated from a negative binomial regression model, adjusted for age group and baseline number of T2 hyperintense lesions.
  • Part 1: BG00012 vs Part 1: Interferon β-1a · Negative binomial regression model · p = =0.0002 · Lesion mean ratio: 0.38 · 95% CI 0.23 to 0.62Estimated from a negative binomial regression model, adjusted for age group and baseline number of T2 hyperintense lesions.
SecondaryPart 1: Proportion of Participants Free of New or Newly Enlarging T2 Hyperintense Lesions on Brain MRI Scans

Participants who were free of new or newly enlarging T2 hyperintense lesions were assessed on Brain MRI scans.

Time frame:
At Weeks 24 and 48
Reported as:
Number · proportion of participants
Part 1: Proportion of Participants Free of New or Newly Enlarging T2 Hyperintense Lesions on Brain MRI Scans
proportion of participantsPart 1: BG00012Part 1: Interferon β-1a
Week 240.200 (0.116 to 0.308)0.141 (0.066 to 0.250)
Week 480.192 (0.109 to 0.301)0.088 (0.029 to 0.193)
SecondaryPart 1: Proportion of Participants Free of New MRI Activity as Measured by Brain MRI Scans

Participants free of Gd-enhancing MRI lesions and new or newly enlarging T2 MRI lesions were assessed on Brain MRI Scans.

Time frame:
At Weeks 24, 48, and 96
Reported as:
Number · proportion of participants
Part 1: Proportion of Participants Free of New MRI Activity as Measured by Brain MRI Scans
proportion of participantsPart 1: BG00012Part 1: Interferon β-1a
Week 240.200 (0.116 to 0.308)0.141 (0.066 to 0.250)
Week 480.178 (0.098 to 0.285)0.088 (0.029 to 0.193)
Week 960.145 (0.069 to 0.258)0.048 (0.006 to 0.162)
SecondaryPart 1: Time to First Relapse

Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the examining neurologist. The time to first relapse was defined as the time from the first dose in Part 1 up to the first relapse. Time to First Relapse was estimated by Kaplan-Meier method.

Time frame:
Up to Week 96
Reported as:
Median · weeks
Part 1: Time to First Relapse
weeksPart 1: BG00012Part 1: Interferon β-1a
Part 1: Time to First RelapseNA (48.4 to NA)NA (30.4 to NA)
Statistical analysis
  • Part 1: BG00012 vs Part 1: Interferon β-1a · Cox proportional hazards model · p = =0.0505 · Hazard ratio (hr): 0.574 · 95% CI 0.329 to 1.001Based on a Cox proportional hazards model, adjusted for baseline relapse rate, age group and baseline Expanded Disability Status Scale (EDSS).
SecondaryPart 1: Proportion of Relapse-Free Participants

Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 24 hours, and accompanied by new objective neurological findings upon examination by the examining neurologist. The proportion of relapse-free participants was estimated using the Kaplan-Meier method.

Time frame:
Up to Week 96
Reported as:
Number · proportion of participants
Part 1: Proportion of Relapse-Free Participants
proportion of participantsPart 1: BG00012Part 1: Interferon β-1a
24 Weeks0.8680.767
48 Weeks0.7610.704
72 Weeks0.6910.652
96 Weeks0.6620.523
SecondaryPart 1: Annualized Relapse Rate (ARR)

ARR is calculated as the total number of relapses that occurred during the study divided by the total number of participant-years. ARR was analyzed using negative binomial regression model.

Time frame:
At Weeks 48 and 96
Reported as:
Number · relapses per participant-year
Part 1: Annualized Relapse Rate (ARR)
relapses per participant-yearPart 1: BG00012Part 1: Interferon β-1a
Week 480.324 (0.188 to 0.560)0.564 (0.342 to 0.931)
Week 960.240 (0.147 to 0.393)0.528 (0.333 to 0.836)
Statistical analysis
  • Part 1: BG00012 vs Part 1: Interferon β-1a · Negative binomial regression model · p = =0.0941 · Rate ratio: 0.575 · 95% CI 0.301 to 1.095Estimated from a negative binomial regression model, adjusted for the baseline relapse rate, baseline EDSS score and age group.
  • Part 1: BG00012 vs Part 1: Interferon β-1a · Negative binomial regression model · p = =0.0063 · Rate ratio: 0.455 · 95% CI 0.260 to 0.797Estimated from a negative binomial regression model, adjusted for the baseline relapse rate, baseline EDSS score and age group.
SecondaryPart 1: Number of Participants With TEAEs and TESAEs

An AE was any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE was any untoward medical occurrence that at any dose resulted in death, in the view of the Investigator, placed the participant at immediate risk of death, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, resulted in a birth defect. TEAEs were defined as AEs occurring or worsening after beginning study treatment (after the first dose).

Time frame:
From Day 1 up to Week 96
Reported as:
Count of participants · Participants
Part 1: Number of Participants With TEAEs and TESAEs
ParticipantsPart 1: BG00012Part 1: Interferon β-1a
TEAEs7469
TESAEs1821
SecondaryPart 1: Change From Baseline in Vital Signs (Temperature)

Negative change from baseline indicated reduction in temperature.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84 and 96
Reported as:
Mean · degree Celsius
Part 1: Change From Baseline in Vital Signs (Temperature)
degree CelsiusPart 1: BG00012Part 1: Interferon β-1a
Baseline36.6 ± 0.3736.5 ± 0.33
Change at Week 40.0 ± 0.330.0 ± 0.27
Change at Week 8-0.1 ± 0.350.0 ± 0.35
Change at Week 12-0.1 ± 0.360.0 ± 0.35
Change at Week 240.0 ± 0.38-0.1 ± 0.38
Change at Week 360.0 ± 0.300.0 ± 0.35
Change at Week 480.0 ± 0.390.0 ± 0.36
Change at Week 600.0 ± 0.330.0 ± 0.36
Change at Week 720.0 ± 0.380.0 ± 0.41
Change at Week 840.0 ± 0.370.0 ± 0.40
Change at Week 960.0 ± 0.370.0 ± 0.37
SecondaryPart 1: Change From Baseline in Vital Signs (Pulse Rate)

Negative change from baseline indicated reduction in pulse rate.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84 and 96
Reported as:
Mean · beats per minute
Part 1: Change From Baseline in Vital Signs (Pulse Rate)
beats per minutePart 1: BG00012Part 1: Interferon β-1a
Baseline76.2 ± 14.9376.7 ± 10.63
Change at Week 42.7 ± 11.53-1.3 ± 10.91
Change at Week 81.7 ± 12.171.1 ± 8.72
Change at Week 122.2 ± 13.600.3 ± 11.77
Change at Week 240.7 ± 12.43-1.2 ± 13.19
Change at Week 360.9 ± 12.931.9 ± 11.72
Change at Week 481.0 ± 16.59-1.2 ± 12.71
Change at Week 602.2 ± 12.70-1.1 ± 10.99
Change at Week 720.0 ± 14.171.3 ± 11.46
Change at Week 840.8 ± 14.30-0.7 ± 12.41
Change at Week 96-0.9 ± 13.92-2.6 ± 11.86
SecondaryPart 1: Change From Baseline in Vital Signs (Blood Pressure)

Negative change from baseline indicated reduction in blood pressure.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84 and 96
Reported as:
Mean · millimeters of mercury (mmHg)
Part 1: Change From Baseline in Vital Signs (Blood Pressure)
millimeters of mercury (mmHg)Part 1: BG00012Part 1: Interferon β-1a
Baseline: Systolic Blood Pressure (SBP)114.2 ± 10.42115.6 ± 10.15
Change at Week 4: SBP1.4 ± 9.00-0.7 ± 8.89
Change at Week 8: SBP2.2 ± 11.07-1.3 ± 11.12
Change at Week 12: SBP0.8 ± 9.750.7 ± 10.46
Change at Week 24: SBP-1.5 ± 10.721.8 ± 9.46
Change at Week 36: SBP1.8 ± 11.030.3 ± 9.13
Change at Week 48: SBP1.3 ± 9.84-1.7 ± 8.76
Change at Week 60: SBP2.8 ± 10.261.5 ± 9.88
Change at Week 72: SBP1.6 ± 11.302.0 ± 12.15
Change at Week 84: SBP2.2 ± 10.561.5 ± 8.82
Change at Week 96: SBP0.9 ± 12.44-0.7 ± 6.36
Baseline: Diastolic Blood Pressure (DBP)68.6 ± 9.2871.4 ± 8.67
Change at Week 4: DBP0.4 ± 9.53-2.2 ± 9.46
Change at Week 8: DBP-0.1 ± 9.22-1.1 ± 8.92
Change at Week 12: DBP0.2 ± 9.00-1.0 ± 8.64
Change at Week 24: DBP-0.1 ± 9.64-1.0 ± 9.24
Change at Week 36: DBP-0.5 ± 9.32-1.2 ± 8.28
Change at Week 48: DBP0.6 ± 8.20-2.3 ± 8.59
Change at Week 60: DBP1.2 ± 11.160.6 ± 9.79
Change at Week 72: DBP1.3 ± 9.820.0 ± 10.28
Change at Week 84: DBP1.2 ± 9.400.5 ± 9.86
Change at Week 96: DBP-0.5 ± 9.99-1.5 ± 9.56
SecondaryPart 1: Change From Baseline in Vital Signs (Respiratory Rate)

Negative change from baseline indicated reduction in respiratory rate.

Time frame:
Baseline, Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84 and 96
Reported as:
Mean · breaths per minute
Part 1: Change From Baseline in Vital Signs (Respiratory Rate)
breaths per minutePart 1: BG00012Part 1: Interferon β-1a
Baseline17.3 ± 2.9618.4 ± 3.02
Change at Week 40.2 ± 2.49-0.3 ± 2.23
Change at Week 80.3 ± 2.620.4 ± 6.19
Change at Week 12-0.1 ± 2.36-0.9 ± 2.91
Change at Week 240.0 ± 2.89-0.5 ± 3.22
Change at Week 360.2 ± 3.54-0.6 ± 2.99
Change at Week 480.0 ± 3.38-0.6 ± 2.86
Change at Week 600.1 ± 3.350.0 ± 2.63
Change at Week 72-0.2 ± 2.27-0.9 ± 3.32
Change at Week 84-0.1 ± 2.82-0.4 ± 3.54
Change at Week 96-0.5 ± 2.74-0.8 ± 2.76
SecondaryPart 1: Number of Participants With Shifts From Baseline in Electrocardiograms (ECG) Abnormalities

Clinical significance of abnormalities in ECG was determined based on the investigator's discretion. Shift to abnormal indicated values that were normal or unknown at baseline and shifted to abnormal values post-baseline.

Time frame:
Up to Week 96
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Shifts From Baseline in Electrocardiograms (ECG) Abnormalities
ParticipantsPart 1: BG00012Part 1: Interferon β-1a
Shift to Abnormal, not adverse event74
Shift to Abnormal, adverse event00
SecondaryPart 1: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Hematology Parameters)

Hematology parameters included leukocytes, erythrocytes, hemoglobin, hematocrit, platelets, eosinophils, lymphocytes, monocytes and neutrophils. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values. The categories with at least one participant with shift from baseline in these parameters are reported.

Time frame:
Baseline up to Week 96
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Hematology Parameters)
ParticipantsPart 1: BG00012Part 1: Interferon β-1a
Leukocytes: Shift to Low3020
Leukocytes: Shift to High65
Erythrocytes: Shift to Low1710
Erythrocytes: Shift to High11
Hemoglobin: Shift to Low95
Hemoglobin: Shift to High10
Hematocrit: Shift to Low1611
Hematocrit: Shift to High00
Platelets: Shift to Low45
Platelets: Shift to High53
Eosinophils: Shift to Low00
Eosinophils: Shift to High2413
Lymphocytes: Shift to Low215
Lymphocytes: Shift to High11
Monocytes: Shift to Low2322
Monocytes: Shift to High13
Neutrophils: Shift to Low109
Neutrophils: Shift to High910
SecondaryPart 1: Change From Baseline in Coagulation Parameters [Activated Partial Thromboplastin Time (aPTT)]

A negative change from baseline indicated a reduction in aPTT.

Time frame:
Baseline, Weeks 24, 48 and 96
Reported as:
Mean · seconds
Part 1: Change From Baseline in Coagulation Parameters [Activated Partial Thromboplastin Time (aPTT)]
secondsPart 1: BG00012Part 1: Interferon β-1a
Baseline26.12 ± 2.44826.48 ± 2.605
Change at Week 240.07 ± 2.406-0.36 ± 2.901
Change at Week 480.16 ± 3.064-0.53 ± 2.631
Change at Week 96-0.38 ± 2.893-0.44 ± 2.657
SecondaryPart 1: Change From Baseline in Coagulation Parameters [Prothrombin Time (PT)]

A negative change from baseline indicated a reduction in PT.

Time frame:
Baseline, Weeks 24, 48 and 96
Reported as:
Mean · seconds
Part 1: Change From Baseline in Coagulation Parameters [Prothrombin Time (PT)]
secondsPart 1: BG00012Part 1: Interferon β-1a
Baseline11.54 ± 2.37911.52 ± 1.172
Change at Week 24-0.04 ± 1.550-0.33 ± 1.343
Change at Week 480.07 ± 3.373-0.45 ± 1.243
Change at Week 96-0.19 ± 2.694-0.19 ± 0.860
SecondaryPart 1: Change From Baseline in Coagulation Parameters [International Normalized Ratio (INR)]

A negative change from baseline indicated a reduction in clotting time.

Time frame:
Baseline, Weeks 24, 48 and 96
Reported as:
Mean · ratio
Part 1: Change From Baseline in Coagulation Parameters [International Normalized Ratio (INR)]
ratioPart 1: BG00012Part 1: Interferon β-1a
Baseline1.08 ± 0.2441.08 ± 0.131
Change at Week 240.0 ± 0.159-0.03 ± 0.153
Change at Week 480.0 ± 0.341-0.05 ± 0.144
Change at Week 96-0.01 ± 0.283-0.01 ± 0.103
SecondaryPart 1: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters)

Parameters included sodium, potassium, chloride, bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, gamma glutamyl transferase, urea nitrogen, creatinine, bicarbonate, calcium, magnesium, phosphate, urate and glucose. These parameters were flagged as low, normal or high relative to parameter's normal range or as unknown if no result was available, by Investigator. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high values postbaseline. Categories with at least one participant with shift from baseline in these parameters are reported.

Time frame:
Baseline up to Week 96
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters)
ParticipantsPart 1: BG00012Part 1: Interferon β-1a
Sodium: Shift to Low00
Sodium: Shift to High12
Potassium: Shift to Low10
Potassium: Shift to High42
Chloride: Shift to Low10
Chloride: Shift to High00
Bilirubin: Shift to Low1212
Bilirubin: Shift to High55
Alkaline Phosphatase: Shift to Low21
Alkaline Phosphatase: Shift to High55
Aspartate Aminotransferase: Shift to Low40
Aspartate Aminotransferase: Shift to High66
Alanine Aminotransferase: Shift to Low21
Alanine Aminotransferase: Shift to High1513
Gamma Glutamyl Transferase: Shift to Low00
Gamma Glutamyl Transferase: Shift to High35
Urea Nitrogen: Shift to Low00
Urea Nitrogen: Shift to High01
Creatinine: Shift to Low51
Creatinine: Shift to High44
Bicarbonate: Shift to Low40
Bicarbonate: Shift to High10
Calcium: Shift to Low00
Calcium: Shift to High1811
Magnesium: Shift to Low01
Magnesium: Shift to High3332
Phosphate: Shift to Low44
Phosphate: Shift to High44
Urate: Shift to Low32
Urate: Shift to High61
Glucose: Shift to Low1913
Glucose: Shift to High2424
SecondaryPart 1: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Urinalysis Parameters)

Urinalysis included assessments of glucose, ketones, occult blood, protein, specific gravity. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available, by the Investigator. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline. The categories with at least one participant with shift from baseline in these parameters are reported.

Time frame:
Baseline up to Week 96
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Urinalysis Parameters)
ParticipantsPart 1: BG00012Part 1: Interferon β-1a
Glucose: Shift to Low00
Glucose: Shift to High21
Ketones: Shift to Low00
Ketones: Shift to High4410
Occult Blood: Shift to Low00
Occult Blood: Shift to High3225
Protein: Shift to Low00
Protein: Shift to High4439
Specific Gravity: Shift to Low00
Specific Gravity: Shift to High44
SecondaryPart 1: Fatigue Score Measured by the Pediatric Quality of Life Inventory (PedsQL) Multidimensional Fatigue Scale

The PedsQL multidimensional fatigue questionnaire was answered by the participant (self-assessment) and parent. The fatigue scale contains 18 questions in 3 fatigue dimensions: general fatigue, sleep/rest fatigue and cognitive fatigue. Each item was scored on 5-point Likert scale (0=never to 4=almost always). Each individual score was then reversed (subtracted from 4) and linearly transformed as follows: 0=100, 1=75, 2=50, 3=25, 4=0. For each dimension, total score was calculated as the sum of all the items/number of items answered. A higher total score indicated fewer problems.

Time frame:
Up to Week 96
Reported as:
Mean · score on a scale
Part 1: Fatigue Score Measured by the Pediatric Quality of Life Inventory (PedsQL) Multidimensional Fatigue Scale
score on a scalePart 1: BG00012Part 1: Interferon β-1a
Participant's Assessment: General Fatigue69.2 ± 23.6474.4 ± 19.89
Participant's Assessment: Sleep/Rest Fatigue67.0 ± 22.5569.2 ± 20.42
Participant's Assessment: Cognitive Fatigue68.1 ± 23.7372.5 ± 23.22
Parent's Assessment: General Fatigue71.1 ± 22.5975.3 ± 18.70
Parent's Assessment: Sleep/Rest Fatigue71.8 ± 20.7769.8 ± 20.82
Parent's Assessment: Cognitive Fatigue71.2 ± 26.9375.0 ± 20.18
Statistical analysis
  • Part 1: BG00012 vs Part 1: Interferon β-1a · ANCOVA · p = =0.3491 (ANCOVA model: dimensional fatigue score as dependent variable and with fixed effects of treatment group, age group and baseline dimensional fatigue score as covariate.) · Least square (ls) mean difference: -3.76 · 95% CI -11.700 to 4.182
  • Part 1: BG00012 vs Part 1: Interferon β-1a · ANCOVA · p = =0.4798 (ANCOVA model: dimensional fatigue score as dependent variable and with fixed effects of treatment group, age group and baseline dimensional fatigue score as covariate.) · Ls mean difference: -2.6 · 95% CI -9.873 to 4.681
  • Part 1: BG00012 vs Part 1: Interferon β-1a · ANCOVA · p = =0.7439 (ANCOVA model: dimensional fatigue score as dependent variable and with fixed effects of treatment group, age group and baseline dimensional fatigue score as covariate.) · Ls mean difference: 1.33 · 95% CI -6.750 to 9.413
  • Part 1: BG00012 vs Part 1: Interferon β-1a · ANCOVA · p = =0.7794 (ANCOVA model: dimensional fatigue score as dependent variable and with fixed effects of treatment group, age group and baseline dimensional fatigue score as covariate.) · Ls mean difference: -1.25 · 95% CI -10.206 to 7.703
  • Part 1: BG00012 vs Part 1: Interferon β-1a · ANCOVA · p = =0.4684 (ANCOVA model: dimensional fatigue score as dependent variable and with fixed effects of treatment group, age group and baseline dimensional fatigue score as covariate.) · Ls mean difference: 3.64 · 95% CI -6.397 to 13.681
  • Part 1: BG00012 vs Part 1: Interferon β-1a · ANCOVA · p = =0.4532 (ANCOVA model: dimensional fatigue score as dependent variable and with fixed effects of treatment group, age group and baseline dimensional fatigue score as covariate.) · Ls mean difference: 3.54 · 95% CI -5.895 to 12.979
SecondaryPart 1: Quality of Life (QOL) as Measured by the PedsQL

The PedsQL QOL questionnaire was answered by the participant (self-assessment) and parent. The QoL scale contains 23 questions in 4 dimensions: Physical Functioning, Emotional Fatigue, Social Fatigue and School Fatigue. Each item was scored on 5-point Likert scale (0=never to 4=almost always). Each individual score was then reversed (subtracted from 4) and linearly transformed as follows: 0=100, 1=75, 2=50, 3=25, 4=0. For each dimension, total score was calculated as the sum of all the items/number of items answered. A higher total score indicated better quality of life.

Time frame:
Up to Week 96
Reported as:
Mean · score on a scale
Part 1: Quality of Life (QOL) as Measured by the PedsQL
score on a scalePart 1: BG00012Part 1: Interferon β-1a
Participant's Assessment: About My Health and Activities79.2 ± 19.4483.1 ± 16.39
Participant's Assessment: About My Feelings67.5 ± 24.5074.4 ± 21.30
Participant's Assessment: How I get Along With Others86.8 ± 17.3993.6 ± 10.25
Participant's Assessment: About Work or School68.5 ± 21.1870.7 ± 21.50
Parent's Assessment: Physical Functioning78.3 ± 22.0783.1 ± 14.89
Parent's Assessment: Emotional Functioning68.1 ± 24.3573.0 ± 23.63
Parent's Assessment: Social Functioning86.7 ± 19.9290.7 ± 15.17
Parent's Assessment: Work/Study/School Functioning71.3 ± 23.0873.9 ± 17.61
Statistical analysis
  • Part 1: BG00012 vs Part 1: Interferon β-1a · ANCOVA · p = =0.0521 (ANCOVA model: dimensional fatigue score as dependent variable and with fixed effects of treatment group, age group and baseline dimensional fatigue score as covariate.) · Ls mean difference: -9.23 · 95% CI -18.547 to 0.088
  • Part 1: BG00012 vs Part 1: Interferon β-1a · ANCOVA · p = =0.0046 (ANCOVA model: dimensional fatigue score as dependent variable and with fixed effects of treatment group, age group and baseline dimensional fatigue score as covariate.) · Ls mean difference: -15.7 · 95% CI -26.283 to -5.123
  • Part 1: BG00012 vs Part 1: Interferon β-1a · ANCOVA · p = =0.0296 (ANCOVA model: dimensional fatigue score as dependent variable and with fixed effects of treatment group, age group and baseline dimensional fatigue score as covariate.) · Ls mean difference: -8.67 · 95% CI -16.440 to -0.903
  • Part 1: BG00012 vs Part 1: Interferon β-1a · ANCOVA · p = =0.5748 (ANCOVA model: dimensional fatigue score as dependent variable and with fixed effects of treatment group, age group and baseline dimensional fatigue score as covariate.) · Ls mean difference: -3.8 · 95% CI -17.385 to 9.775
  • Part 1: BG00012 vs Part 1: Interferon β-1a · ANCOVA · p = =0.4668 (ANCOVA model: dimensional fatigue score as dependent variable and with fixed effects of treatment group, age group and baseline dimensional fatigue score as covariate.) · Ls mean difference: -3.46 · 95% CI -13.027 to 6.113
  • Part 1: BG00012 vs Part 1: Interferon β-1a · ANCOVA · p = =0.7868 (ANCOVA model: dimensional fatigue score as dependent variable and with fixed effects of treatment group, age group and baseline dimensional fatigue score as covariate.) · Ls mean difference: -1.79 · 95% CI -15.207 to 11.619
  • Part 1: BG00012 vs Part 1: Interferon β-1a · ANCOVA · p = =0.4641 (ANCOVA model: dimensional fatigue score as dependent variable and with fixed effects of treatment group, age group and baseline dimensional fatigue score as covariate.) · Ls mean difference: -4.72 · 95% CI -17.710 to 8.268
  • Part 1: BG00012 vs Part 1: Interferon β-1a · ANCOVA · p = =0.5462 (ANCOVA model: dimensional fatigue score as dependent variable and with fixed effects of treatment group, age group and baseline dimensional fatigue score as covariate.) · Ls mean difference: 3.58 · 95% CI -8.397 to 15.566
SecondaryPart 1: Change From Baseline in the Expanded Disability Status Scale (EDSS) Score

The EDSS measures the disability status of participants with multiple sclerosis on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS with higher scores indicating more disability. A negative change from baseline indicated an improvement in the disability.

Time frame:
Baseline, Week 96
Reported as:
Mean · score on a scale
Part 1: Change From Baseline in the Expanded Disability Status Scale (EDSS) Score
score on a scalePart 1: BG00012Part 1: Interferon β-1a
Baseline1.16 ± 1.0741.12 ± 0.966
Change at Week 96-0.03 ± 1.0450.13 ± 0.748
SecondaryPart 2: Annualized Relapse Rate (ARR)

ARR is calculated as the total number of relapses that occurred during the study divided by the total number of participant-years. ARR was analyzed using negative binomial regression model.

Time frame:
From Baseline (Week 96) up to Week 336
Reported as:
Number · relapses per participant-year
Part 2: Annualized Relapse Rate (ARR)
relapses per participant-yearPart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Part 2: Annualized Relapse Rate (ARR)0.141 (0.076 to 0.261)0.182 (0.093 to 0.356)
SecondaryPart 2: Change From Baseline in the Expanded Disability Status Scale (EDSS) Score

The EDSS measures the disability status of participants with multiple sclerosis on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and the subsequent levels 5.0 to 9.5 refer to the loss of ambulatory ability. The range of main categories include (0) = normal neurologic exam; to (5) = ambulatory without aid or rest for 200 meters; disability severe enough to impair full daily activities; to (10) = death due to MS. A negative change from baseline indicated an improvement in the disability.

Time frame:
Baseline (Week 96), Week 336
Reported as:
Mean · score on a scale
Part 2: Change From Baseline in the Expanded Disability Status Scale (EDSS) Score
score on a scalePart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Baseline (Week 96)0.95 ± 0.9511.16 ± 0.983
Change at Week 336-0.11 ± 0.7640.14 ± 0.808
SecondaryPart 2: Change From Baseline in Brief Visuospatial Memory Test - Revised (BVMT-R) Score

BVMT-R is used to assess learning/memory. In this test, six abstract designs are presented for 10 sec. The display is removed from view, and participants render the stimuli via pencil on paper, manual responses. Each design receives from 0 to 2 points, representing accuracy and location. There are three Learning Trials, and the score is reported as the total number of points earned over the trials. Thus, scores range from 0 to 12 per trial; total score range is 0 to 36 for all three trials. Scores were converted to standardized scores using normative data, ranging from 2-86. The lower the score, the more severe the cognitive impairment while higher scores reflect better visuospatial memory.

Time frame:
Baseline (Week 96), Weeks 144,192, 240, 288 and 336
Reported as:
Mean · score on a scale
Part 2: Change From Baseline in Brief Visuospatial Memory Test - Revised (BVMT-R) Score
score on a scalePart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Trial 1: Baseline (Week 96)7.33 ± 2.5456.50 ± 2.502
Trial 1: Change at Week 144-0.33 ± 2.6630.55 ± 2.420
Trial 1: Change at Week 1920.86 ± 2.3900.92 ± 2.216
Trial 1: Change at Week 2400.04 ± 1.8371.78 ± 2.636
Trial 1: Change at Week 2880.95 ± 1.5721.29 ± 2.901
Trial 1: Change at Week 336-0.13 ± 2.4751.00 ± 1.886
Trial 2: Baseline (Week 96)9.41 ± 2.4328.91 ± 2.441
Trial 2: Change at Week 144-0.42 ± 2.5720.00 ± 2.582
Trial 2: Change at Week 1920.89 ± 2.3740.48 ± 2.257
Trial 2: Change at Week 2400.00 ± 2.2550.59 ± 2.024
Trial 2: Change at Week 2880.50 ± 1.2770.48 ± 2.064
Trial 2: Change at Week 336-0.27 ± 1.5340.79 ± 1.584
Trial 3: Baseline (Week 96)9.98 ± 1.9959.59 ± 2.014
Trial 3: Change at Week 144-0.27 ± 2.5800.10 ± 2.166
Trial 3: Change at Week 1920.71 ± 1.6550.36 ± 2.119
Trial 3: Change at Week 2400.24 ± 1.8320.19 ± 2.370
Trial 3: Change at Week 2880.00 ± 2.3400.48 ± 1.914
Trial 3: Change at Week 3360.00 ± 1.5580.37 ± 1.606
SecondaryPart 2: Change From Baseline in Symbol Digit Modalities Test (SDMT) Score

SDMT is used to assess processing speed. It consists of 9 abstract symbols. Each symbol is paired with a single digit. The participant is provided with a key, showing each symbol digit pair. In addition, the participants are shown several rows of the 9 symbols, which are arranged pseudo-randomly, without the digit. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 seconds. The SDMT score ranges from 0 to 110, where higher scores indicate improvement in cognitive functioning and lower scores indicate worsening.

Time frame:
Baseline (Week 96), Weeks 144,192, 240, 288 and 336
Reported as:
Mean · score on a scale
Part 2: Change From Baseline in Symbol Digit Modalities Test (SDMT) Score
score on a scalePart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Baseline (Week 96)61.34 ± 13.05360.42 ± 11.198
Change at Week 1440.37 ± 8.5754.03 ± 10.108
Change at Week 1922.43 ± 7.5305.60 ± 9.583
Change at Week 2404.54 ± 6.6718.70 ± 10.791
Change at Week 2886.71 ± 13.7129.81 ± 10.172
Change at Week 3365.53 ± 8.3838.89 ± 12.364
SecondaryPart 2: Number of Participants With or Without School Progression

Participants or caregivers were posed the following question: "During the past year, did \[you/the participant\] progress from one \[class/grade-level\] to the next in school?" Responses were recorded as Yes (participant advanced to the next grade) or No (participant did not advance).

Time frame:
At Weeks 144, 192, 240, 288 and 336
Reported as:
Count of participants · Participants
Part 2: Number of Participants With or Without School Progression
ParticipantsPart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Week 144 — Yes4119
Week 144 — No15
Week 192 — Yes2720
Week 192 — No11
Week 240 — Yes1817
Week 240 — No11
Week 288 — Yes1513
Week 288 — No22
Week 336 — Yes3517
Week 336 — No55
SecondaryPart 2: Change From Baseline in Vital Signs (Temperature)

Negative change from baseline indicated reduction in temperature.

Time frame:
Baseline (Week 96), Weeks 120,144, 168, 192, 216, 240, 264, 288, 312, 336, and 340
Reported as:
Mean · degree Celsius
Part 2: Change From Baseline in Vital Signs (Temperature)
degree CelsiusPart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Baseline (Week 96)36.54 ± 0.40036.44 ± 0.243
Change at Week 120-0.03 ± 0.4010.07 ± 0.236
Change at Week 144-0.04 ± 0.4110.06 ± 0.283
Change at Week 168-0.04 ± 0.4080.04 ± 0.280
Change at Week 192-0.01 ± 0.462-0.03 ± 0.284
Change at Week 2160.00 ± 0.4550.00 ± 0.249
Change at Week 240-0.10 ± 0.3810.05 ± 0.242
Change at Week 264-0.10 ± 0.359-0.01 ± 0.307
Change at Week 288-0.16 ± 0.4420.04 ± 0.202
Change at Week 312-0.04 ± 0.3580.00 ± 0.344
Change at Week 336-0.23 ± 0.581-0.02 ± 0.246
Change at Week 340-0.09 ± 0.4350.00 ± 0.331
SecondaryPart 2: Change From Baseline in Vital Signs (Pulse Rate)

Negative change from baseline indicated reduction in pulse rate.

Time frame:
Baseline (Week 96), Weeks 120,144, 168, 192, 216, 240, 264, 288, 312, 336, and 340
Reported as:
Mean · beats per minute
Part 2: Change From Baseline in Vital Signs (Pulse Rate)
beats per minutePart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Baseline (Week 96)75.1 ± 11.7275.5 ± 12.47
Change at Week 1201.3 ± 12.373.4 ± 8.99
Change at Week 1440.7 ± 10.673.1 ± 10.30
Change at Week 168-2.7 ± 9.503.2 ± 12.88
Change at Week 1920.0 ± 11.063.6 ± 12.23
Change at Week 2166.2 ± 16.044.0 ± 13.88
Change at Week 2401.2 ± 12.631.4 ± 10.01
Change at Week 2643.1 ± 13.870.5 ± 13.34
Change at Week 2882.2 ± 12.91-0.1 ± 12.86
Change at Week 3120.7 ± 14.82-2.8 ± 12.78
Change at Week 336-6.9 ± 14.180.1 ± 14.02
Change at Week 3401.8 ± 10.81-0.9 ± 12.86
SecondaryPart 2: Change From Baseline in Vital Signs (Blood Pressure)

Negative change from baseline indicated reduction in blood pressure.

Time frame:
Baseline (Week 96), Weeks 120,144, 168, 192, 216, 240, 264, 288, 312, 336, and 340
Reported as:
Mean · mmHg
Part 2: Change From Baseline in Vital Signs (Blood Pressure)
mmHgPart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Baseline (Week 96): SBP114.5 ± 10.99114.3 ± 7.83
Change at Week 120: SBP0.5 ± 11.053.2 ± 9.62
Change at Week 144: SBP2.1 ± 10.852.7 ± 11.61
Change at Week 168: SBP1.7 ± 11.285.3 ± 6.65
Change at Week 192: SBP1.4 ± 10.223.1 ± 10.20
Change at Week 216: SBP3.9 ± 9.283.6 ± 9.64
Change at Week 240: SBP4.3 ± 11.263.2 ± 9.81
Change at Week 264: SBP5.6 ± 7.354.5 ± 5.52
Change at Week 288: SBP6.6 ± 12.214.0 ± 8.48
Change at Week 312: SBP5.1 ± 11.481.8 ± 9.17
Change at Week 336: SBP4.8 ± 8.910.8 ± 9.66
Change at Week 340: SBP6.5 ± 7.924.1 ± 8.84
Baseline (Week 96): DBP67.8 ± 8.8270.5 ± 8.62
Change at Week 120: DBP2.3 ± 8.512.2 ± 7.22
Change at Week 144: DBP1.4 ± 8.511.9 ± 7.49
Change at Week 168: DBP2.9 ± 9.500.1 ± 8.72
Change at Week 192: DBP3.8 ± 9.550.9 ± 8.29
Change at Week 216: DBP5.9 ± 9.910.1 ± 9.75
Change at Week 240: DBP4.9 ± 10.080.9 ± 7.38
Change at Week 264: DBP4.6 ± 8.17-0.3 ± 7.26
Change at Week 288: DBP3.6 ± 10.810.7 ± 7.88
Change at Week 312: DBP5.6 ± 10.852.2 ± 8.77
Change at Week 336: DBP7.3 ± 9.660.2 ± 8.94
Change at Week 340: DBP5.3 ± 8.392.3 ± 9.96
SecondaryPart 2: Change From Baseline in Vital Signs (Respiratory Rate)

Negative change from baseline indicated reduction in respiratory rate.

Time frame:
Baseline (Week 96), Weeks 120,144, 168, 192, 216, 240, 264, 288, 312, 336, and 340
Reported as:
Mean · breaths per minute
Part 2: Change From Baseline in Vital Signs (Respiratory Rate)
breaths per minutePart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Baseline (Week 96)16.8 ± 2.4216.9 ± 2.55
Change at Week 1200.4 ± 2.760.5 ± 2.29
Change at Week 1440.3 ± 2.070.0 ± 2.34
Change at Week 1680.4 ± 2.500.5 ± 3.10
Change at Week 1920.5 ± 2.740.7 ± 3.36
Change at Week 216-0.2 ± 2.570.4 ± 2.57
Change at Week 2400.0 ± 1.960.6 ± 3.00
Change at Week 264-0.2 ± 1.88-0.1 ± 2.59
Change at Week 288-0.1 ± 3.08-0.1 ± 2.43
Change at Week 3120.3 ± 2.63-0.5 ± 2.42
Change at Week 336-1.7 ± 3.040.4 ± 2.79
Change at Week 340-0.4 ± 3.200.6 ± 2.87
SecondaryPart 2: Number of Participants With Shifts From Baseline in ECG Abnormalities

Clinical significance of abnormalities in ECG was determined based on the investigator's discretion. Shift to abnormal indicated values that were normal or unknown at baseline and shifted to abnormal values post-baseline.

Time frame:
From Baseline (Week 96) to Week 336
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Shifts From Baseline in ECG Abnormalities
ParticipantsPart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Shift to Abnormal, not adverse event51
Shift to Abnormal, adverse event00
SecondaryPart 2: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Hematology Parameters)

Hematology parameters included leukocytes, erythrocytes, hemoglobin, hematocrit, platelets, eosinophils, lymphocytes, monocytes and neutrophils. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline values. The categories with at least one participant with shift from baseline in these parameters are reported.

Time frame:
Baseline (Week 96) up to Week 340
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Hematology Parameters)
ParticipantsPart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Leukocytes: Shift to Low1211
Leukocytes: Shift to High48
Erythrocytes: Shift to Low99
Erythrocytes: Shift to High11
Hemoglobin: Shift to Low54
Hemoglobin: Shift to High10
Hematocrit: Shift to Low75
Hematocrit: Shift to High12
Platelets: Shift to Low64
Platelets: Shift to High20
Eosinophils: Shift to Low00
Eosinophils: Shift to High23
Lymphocytes: Shift to Low811
Lymphocytes: Shift to High00
Monocytes: Shift to Low1010
Monocytes: Shift to High22
Neutrophils: Shift to Low124
Neutrophils: Shift to High712
SecondaryPart 2: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters)

Parameters included potassium, bilirubin, alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma glutamyl transferase, urea nitrogen, creatinine, bicarbonate, calcium, magnesium, phosphate, urate and glucose. These parameters were flagged as low, normal or high relative to parameter's normal range or as unknown if no result was available, by Investigator. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high values postbaseline. Categories with at least one participant with shift from baseline in these parameters are reported.

Time frame:
Baseline (Week 96) up to Week 340
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Blood Chemistry Parameters)
ParticipantsPart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Potassium: Shift to Low00
Potassium: Shift to High33
Bilirubin: Shift to Low43
Bilirubin: Shift to High14
Alkaline Phosphatase: Shift to Low12
Alkaline Phosphatase: Shift to High12
Alanine Aminotransferase: Shift to Low10
Alanine Aminotransferase: Shift to High79
Aspartate Aminotransferase: Shift to Low00
Aspartate Aminotransferase: Shift to High77
Gamma Glutamyl Transferase: Shift to Low50
Gamma Glutamyl Transferase: Shift to High02
Urea Nitrogen: Shift to Low00
Urea Nitrogen: Shift to High01
Creatinine: Shift to Low22
Creatinine: Shift to High02
Bicarbonate: Shift to Low44
Bicarbonate: Shift to High10
Calcium: Shift to Low10
Calcium: Shift to High76
Magnesium: Shift to Low11
Magnesium: Shift to High196
Phosphate: Shift to Low03
Phosphate: Shift to High25
Urate: Shift to Low12
Urate: Shift to High22
Glucose: Shift to Low42
Glucose: Shift to High1316
SecondaryPart 2: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Urinalysis Parameters)

Urinalysis included assessments of erythrocytes, leukocytes and specific gravity. These parameters were flagged as low, normal, or high relative to parameter's normal range or as unknown if no result was available, by the Investigator. Here, shift to low indicated values that were normal, high or unknown at baseline and shifted to low values postbaseline. Shift to high indicated values that were normal, low or unknown at baseline and shifted to high postbaseline. The categories with at least one participant with shift from baseline in these parameters are reported.

Time frame:
Baseline up to Week 340
Reported as:
Count of participants · Participants
Part 2: Number of Participants With Shifts From Baseline in Clinical Laboratory Parameters (Urinalysis Parameters)
ParticipantsPart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Erythrocytes: Shift to Low00
Erythrocytes: Shift to High1411
Leukocytes: Shift to Low00
Leukocytes: Shift to High56
Specific Gravity: Shift to Low00
Specific Gravity: Shift to High98
SecondaryPart 2: Change From Baseline in Height
Time frame:
Baseline (Week 96), Weeks 120,144, 168, 192, 216, 240, 264, 288, 312, 336, and 340
Reported as:
Mean · centimeters (cm)
Part 2: Change From Baseline in Height
centimeters (cm)Part 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Baseline (Week 96)167.5 ± 7.09169.0 ± 9.37
Change at Week 1200.36 ± 1.5920.76 ± 2.878
Change at Week 1440.72 ± 1.9161.67 ± 4.021
Change at Week 1681.13 ± 3.1201.92 ± 4.855
Change at Week 1921.37 ± 3.3062.14 ± 5.407
Change at Week 2161.71 ± 3.6042.47 ± 5.654
Change at Week 2401.85 ± 3.8622.52 ± 5.858
Change at Week 2642.16 ± 4.3362.75 ± 6.661
Change at Week 2882.37 ± 4.7773.09 ± 7.743
Change at Week 3122.29 ± 4.8783.62 ± 8.121
Change at Week 3361.94 ± 4.8303.03 ± 7.019
Change at Week 3403.32 ± 6.6914.17 ± 8.611
SecondaryPart 2: Change From Baseline in Weight
Time frame:
Baseline (Week 96), Weeks 120,144, 168, 192, 216, 240, 264, 288, 312, 336, and 340
Reported as:
Mean · kilograms (Kg)
Part 2: Change From Baseline in Weight
kilograms (Kg)Part 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Baseline (Week 96)67.5 ± 14.6765.1 ± 13.59
Change at Week 1200.45 ± 3.6420.93 ± 2.675
Change at Week 1440.97 ± 3.9792.32 ± 4.692
Change at Week 1681.15 ± 4.3222.54 ± 6.622
Change at Week 1921.27 ± 4.7404.68 ± 8.084
Change at Week 2161.65 ± 5.7125.74 ± 8.983
Change at Week 2400.83 ± 8.6845.90 ± 9.945
Change at Week 2643.73 ± 6.8066.99 ± 11.307
Change at Week 2884.24 ± 7.2967.17 ± 7.584
Change at Week 3124.48 ± 8.1168.04 ± 8.116
Change at Week 3366.35 ± 6.9957.49 ± 8.993
Change at Week 3407.25 ± 7.4578.29 ± 8.310
SecondaryPart 2: Change From Baseline in Bone Age

Bone age was tested until the participant reached a bone age of 16 years.

Time frame:
Baseline (Week 96), Weeks 144, 192 and 240
Reported as:
Mean · Years
Part 2: Change From Baseline in Bone Age
YearsPart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Baseline (Week 96)14.46 ± 0.87714.17 ± 0.983
Change at Week 1440.50 ± 0.5770.50 ± 0.707
Change at Week 1922.00 ± 0.0001.50 ± 0.707
Change at Week 240—2.00 ± NA
SecondaryPart 2: Number of Male Participants by Tanner Stage Assessment

Tanner pubertal staging in males was assessed for testes and scrotum development and pubic hair growth, progressing from stage 1 (prepubertal) to stage 5 (adult). Assessments ended when bone age reached ≥16 years. Testes and scrotum stages were: 1-prepubertal; 2-enlargement of testes, scrotum reddens, texture change; 3-Enlargement of penis, further growth of testes; 4-Increased size of penis with growth in breadth and development of glans; testes and scrotum larger, scrotum skin darker; 5-adult genitalia. Pubic hair stages were: 1-prepubertal; 2-Sparse growth of long, slightly pigmented hair, straight or curled; 3-Darker, coarser and more curled hair, spreading sparsely over junction of pubes; 4-Hair adult in type, but covering smaller area than in adult; no spread to medial surface of thighs; 5-Adult in type and quantity, with horizontal distribution.

Time frame:
At Weeks 96, 144, 192, 240, 288 and 336
Reported as:
Count of participants · Participants
Part 2: Number of Male Participants by Tanner Stage Assessment
ParticipantsPart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Testes and Scrotum, Week 96, Stage 100
Testes and Scrotum, Week 96, Stage 211
Testes and Scrotum, Week 96, Stage 301
Testes and Scrotum, Week 96, Stage 441
Testes and Scrotum, Week 96, Stage 593
Pubic hair, Week 96, Stage 100
Pubic hair, Week 96, Stage 211
Pubic hair, Week 96, Stage 301
Pubic hair, Week 96, Stage 441
Pubic hair, Week 96, Stage 593
Testes and Scrotum, Week 144, Stage 100
Testes and Scrotum, Week 144, Stage 200
Testes and Scrotum, Week 144, Stage 310
Testes and Scrotum, Week 144, Stage 412
Testes and Scrotum, Week 144, Stage 522
Pubic hair, Week 144, Stage 100
Pubic hair, Week 144, Stage 200
Pubic hair, Week 144, Stage 310
Pubic hair, Week 144, Stage 412
Pubic hair, Week 144, Stage 522
Testes and Scrotum, Week 192, Stage 100
Testes and Scrotum, Week 192, Stage 200
Testes and Scrotum, Week 192, Stage 300
Testes and Scrotum, Week 192, Stage 413
Testes and Scrotum, Week 192, Stage 531
Pubic hair, Week 192, Stage 100
Pubic hair, Week 192, Stage 200
Pubic hair, Week 192, Stage 300
Pubic hair, Week 192, Stage 413
Pubic hair, Week 192, Stage 531
Testes and Scrotum, Week 240, Stage 100
Testes and Scrotum, Week 240, Stage 200
Testes and Scrotum, Week 240, Stage 300
Testes and Scrotum, Week 240, Stage 401
Testes and Scrotum, Week 240, Stage 522
Pubic hair, Week 240, Stage 100
Pubic hair, Week 240, Stage 200
Pubic hair, Week 240, Stage 300
Pubic hair, Week 240, Stage 401
Pubic hair, Week 240, Stage 522
Testes and Scrotum, Week 288, Stage 100
Testes and Scrotum, Week 288, Stage 200
Testes and Scrotum, Week 288, Stage 300
Testes and Scrotum, Week 288, Stage 400
Testes and Scrotum, Week 288, Stage 505
Pubic hair, Week 288, Stage 100
Pubic hair, Week 288, Stage 200
Pubic hair, Week 288, Stage 300
Pubic hair, Week 288, Stage 400
Pubic hair, Week 288, Stage 505
Testes and Scrotum, Week 336, Stage 100
Testes and Scrotum, Week 336, Stage 200
Testes and Scrotum, Week 336, Stage 300
Testes and Scrotum, Week 336, Stage 421
Testes and Scrotum, Week 336, Stage 515
Pubic hair, Week 336, Stage 100
Pubic hair, Week 336, Stage 200
Pubic hair, Week 336, Stage 300
Pubic hair, Week 336, Stage 421
Pubic hair, Week 336, Stage 515
SecondaryPart 2: Number of Female Participants by Tanner Stage Assessment

Tanner pubertal staging in females was assessed for breast development and pubic hair growth, progressing from stage 1 (prepubertal) to stage 5 (adult). Assessments ended when bone age reached ≥16 years or the participant was post-menarche. Breast development stages: 1-prepubertal; 2-breast bud stage with elevation of breast and papilla; enlargement of areola, 3-further enlargement of breast and areola; no separation of their contour; 4-areola and papilla form secondary mound above level of breast; 5-mature stage: projection of papilla only, related to recession of areola. Pubic hair stages: 1-prepubertal (can see velus hair similar to abdominal wall); 2-sparse growth of long, slightly pigmented hair, straight or curled, mainly on labia; 3-Darker, coarser and more curled hair, spreading sparsely over junction of pubes; 4-hair adult in type, but covering smaller area than in adult; no spread to medial surface of thighs; 5-adult in type and quantity, with horizontal distribution.

Time frame:
At Weeks 96, 144, 192, 240, 288 and 336
Reported as:
Count of participants · Participants
Part 2: Number of Female Participants by Tanner Stage Assessment
ParticipantsPart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Breasts, Week 96, Stage 100
Breasts, Week 96, Stage 200
Breasts, Week 96, Stage 300
Breasts, Week 96, Stage 463
Breasts, Week 96, Stage 565
Pubic hair, Week 96, Stage 100
Pubic hair, Week 96, Stage 200
Pubic hair, Week 96, Stage 300
Pubic hair, Week 96, Stage 464
Pubic hair, Week 96, Stage 564
Breasts, Week 144, Stage 100
Breasts, Week 144, Stage 200
Breasts, Week 144, Stage 300
Breasts, Week 144, Stage 430
Breasts, Week 144, Stage 532
Pubic hair, Week 144, Stage 100
Pubic hair, Week 144, Stage 200
Pubic hair, Week 144, Stage 300
Pubic hair, Week 144, Stage 430
Pubic hair, Week 144, Stage 532
Breasts, Week 192, Stage 100
Breasts, Week 192, Stage 200
Breasts, Week 192, Stage 300
Breasts, Week 192, Stage 400
Breasts, Week 192, Stage 510
Pubic hair, Week 192, Stage 100
Pubic hair, Week 192, Stage 200
Pubic hair, Week 192, Stage 300
Pubic hair, Week 192, Stage 400
Pubic hair, Week 192, Stage 510
Breasts, Week 240, Stage 100
Breasts, Week 240, Stage 200
Breasts, Week 240, Stage 300
Breasts, Week 240, Stage 400
Breasts, Week 240, Stage 500
Pubic hair, Week 240, Stage 100
Pubic hair, Week 240, Stage 200
Pubic hair, Week 240, Stage 300
Pubic hair, Week 240, Stage 400
Pubic hair, Week 240, Stage 500
Breasts, Week 288, Stage 100
Breasts, Week 288, Stage 200
Breasts, Week 288, Stage 300
Breasts, Week 288, Stage 400
Breasts, Week 288, Stage 500
Pubic hair, Week 288, Stage 100
Pubic hair, Week 288, Stage 200
Pubic hair, Week 288, Stage 300
Pubic hair, Week 288, Stage 400
Pubic hair, Week 288, Stage 500
Breasts, Week 336, Stage 100
Breasts, Week 336, Stage 200
Breasts, Week 336, Stage 300
Breasts, Week 336, Stage 400
Breasts, Week 336, Stage 510
Pubic hair, Week 336, Stage 100
Pubic hair, Week 336, Stage 200
Pubic hair, Week 336, Stage 300
Pubic hair, Week 336, Stage 400
Pubic hair, Week 336, Stage 510

Adverse events

Collected over From first dose of study drug up to last follow-up visit (Week 340). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: BG000120/78 (0%)18/78 (23.1%)74/78 (94.9%)
Part 1: Interferon β-1a0/72 (0%)21/72 (29.2%)69/72 (95.8%)
Part 2: BG00012/ BG000120/57 (0%)8/57 (14%)48/57 (84.2%)
Part 2: IFN β-1a/ BG000120/35 (0%)2/35 (5.7%)31/35 (88.6%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventPart 1: BG00012Part 1: Interferon β-1aPart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Multiple sclerosis relapseNervous system disorders13/7818/723/572/35
Optic neuritisNervous system disorders1/780/721/571/35
Congenital cystic kidney diseaseCongenital, familial and genetic disorders0/780/721/570/35
Herpes zosterInfections and infestations0/780/721/570/35
Joint dislocationInjury, poisoning and procedural complications0/780/721/570/35
WoundInjury, poisoning and procedural complications0/780/721/570/35
EpilepsyNervous system disorders1/780/721/570/35
SyncopeNervous system disorders0/780/721/570/35
Abortion missedPregnancy, puerperium and perinatal conditions0/780/721/570/35
Borderline personality disorderPsychiatric disorders0/780/721/570/35
Most frequent other events
Showing 10 of 56
Most frequent other events
EventPart 1: BG00012Part 1: Interferon β-1aPart 2: BG00012/ BG00012Part 2: IFN β-1a/ BG00012
Influenza like illnessGeneral disorders2/7836/720/571/35
Multiple sclerosis relapseNervous system disorders23/7823/7215/5716/35
Abdominal painGastrointestinal disorders32/785/727/575/35
FlushingVascular disorders30/781/724/5710/35
HeadacheNervous system disorders22/7826/7213/572/35
PyrexiaGeneral disorders8/7817/7210/574/35
VomitingGastrointestinal disorders18/786/725/573/35
NasopharyngitisInfections and infestations18/789/728/578/35
Covid-19Infections and infestations0/780/7211/578/35
ErythemaSkin and subcutaneous tissue disorders8/780/723/577/35

Baseline characteristics

Intent-to-Treat (ITT) set included all participants who were randomized and received at least one dose of study treatment. Ethnicity data was not collected in this study.

Age, Continuous
Age, Continuous(Years)Part 1: BG00012Part 1: Interferon β-1aTotal
Mean14.9 ± 1.6115.0 ± 1.6414.9 ± 1.62
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: BG00012Part 1: Interferon β-1aTotal
Female5249101
Male262349
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: BG00012Part 1: Interferon β-1aTotal
Race — White111425
Race — Asian112
Race — Not Reported due to Confidentiality Regulations272653
Race — Other303
Race — Unknown/Missing363167
08

Study locations

62 sites
  • Boston Children's Hospital
    Boston, Massachusetts 2115, United States
  • The Rector and Visitors of the University of Virginia
    Charlottesville, Virginia 22903, United States
  • Universitair Kinderziekenhuis Koningin Fabiola
    Brussels, 1020, Belgium
  • Universitair Ziekenhuis Ghent
    Ghent, 9000, Belgium
  • MHATNP 'Sv.Naum', EAD
    Sofia, 1113, Bulgaria
  • University of Calgary - Alberta Children's Hospital
    Calgary, Alberta T3B 6A8, Canada
  • Fakultni nemocnice u sv. Anny v Brne
    Brno, 656 91, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Králové, 500 05, Czechia
  • Nemocnice Jihlava p.o.
    Jihlava, 58633, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava, 708 52, Czechia
  • Århus Universitetshospital
    Aarhus N, 8200, Denmark
  • Rigshospitalet
    Copenhagen, 2100, Denmark
  • Odense Universitetshospital
    Odense, 5000, Denmark
  • CHU Strasbourg - Hôpital Hautepierre
    Strasbourg, Bas Rhin 67098, France
  • Hôpital de la Timone
    Marseille, Bouches-du-Rhône 13385, France
  • CHU Dijon -BOCAGE CENTRAL
    Dijon, Côte-d'Or 21079, France
  • Hopital Gui de Chauliac
    Montpellier, Herault 34295, France
  • CHU Rennes - Hopital Pontchaillou
    Rennes, Ille Et Vilaine 35033, France
  • Hôpital de Brabois Enfants
    Vandœuvre-lès-Nancy, Meurthe Et Moselle 54500, France
  • Hopital Roger Salengro - CHU Lille
    Lille, Nord 59037, France
  • CHU Clermont Ferrand - Hôpital d'Estaing
    Clermont-Ferrand, Puy De Dome 63003, France
  • Hopital Neurologique Pierre Wertheimer
    Bron, Rhone 69677, France
  • CHU Amiens - Hopital Sud
    Amiens, Somme 80054, France
  • Hôpital Bicêtre
    Le Kremlin-Bicêtre, Val De Marne 94275, France
  • Universitaetsklinikum Augsburg
    Augsburg, Bavaria 86156, Germany
  • Klinikum der Universitaet Muenchen
    Munich, Bavaria 80337, Germany
  • Katholisches Klinikum Bochum gGmbH
    Bochum, North Rhine-Westphalia 44791, Germany
  • Semmelweis Egyetem
    Budapest, 1083, Hungary
  • Heim Pal Orszagos Gyermekgyogyaszati Intezet
    Budapest, 1089, Hungary
  • Hadassah University Hospital - Ein Kerem
    Jerusalem, 91120, Israel
  • Schneider Children's Medical Center
    Petah Tikva, 4920235, Israel
  • Chaim Sheba Medical Center
    Ramat Gan, 5265601, Israel
  • Azienda Socio Sanitaria Territoriale della Valle Olona (presidio di Gallarate)
    Gallarate, Varese 21013, Italy
  • Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
    Bari, 70124, Italy
  • IRCCS Ospedale Policlinico San Martino
    Genova, 16132, Italy
  • Ospedale San Raffaele
    Milan, 20132, Italy
  • Azienda Ospedaliera Universitaria 'Federico II'
    Naples, 80131, Italy
  • Azienda Ospedale-Università di Padova
    Padova, 35128, Italy
  • Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
    Palermo, 90127, Italy
  • Ospedale Pediatrico Bambino Gesù
    Roma, 00165, Italy
  • Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza
    Roma, 00189, Italy
  • Ibn Sina Hospital
    Ash Shuwaykh, 12345, Kuwait
  • SPZOZ Uniwersytecki Dzieciecy Szpital Kliniczny im. L. Zamenhofa
    Bialystok, 15-274, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-211, Poland
  • Instytut Centrum Zdrowia Matki Polki
    Lodz, 93-338, Poland
  • Szpital Kliniczny im.Heliodora Swiecickiego Uniwersytetu Medycznego im.K. Marcinkowskiego w Poznaniu
    Poznan, 60-355, Poland
  • Instytut 'Pomnik - Centrum Zdrowia Dziecka'
    Warsaw, 04-730, Poland
  • Clinic of Neurology and Psychiatry for Children and Youth
    Belgrade, 11000, Serbia
  • Mother and Child Health Care Institute of Serbia ,,Dr Vukan Cupic''
    Belgrade, 11000, Serbia
  • University Clinical Center Kragujevac
    Kragujevac, 34000, Serbia
  • Hospital Sant Joan de Deu
    Esplugues de Llobregat, Barcelona 8950, Spain
  • Hospital Universitario Reina Sofia
    Córdoba, Córdoba 14011, Spain
  • Hospital Universitario de Torrejon
    Torrejón de Ardoz, Madrid 28850, Spain
  • Hospital Universitario Virgen Macarena
    Seville, 41009, Spain
  • Sahlgrenska Sjukhuset
    Gothenburg, 41345, Sweden
  • Karolinska
    Stockholm, SE-113 61, Sweden
  • Hacettepe University Medical Faculty
    Ankara, 06100, Turkey (Türkiye)
  • Akdeniz University Faculty of Medicine
    Antalya, 07070, Turkey (Türkiye)
  • Evelina London Children's Hospital
    London, Greater London SE1 7EH, United Kingdom
  • The National Hospital for Neurology & Neurosurgery
    London, Greater London WC1N 3BG, United Kingdom
  • Great Ormond Street Hospital for Children
    London, Greater London WC1N 3JH, United Kingdom
  • Birmingham Children's Hospital
    Birmingham, West Midlands B4 6NH, United Kingdom
09

References and documents

Publications

  • Vermersch P, Scaramozza M, Levin S, Alroughani R, Deiva K, Pozzilli C, Lyons J, Mokliatchouk O, Pultz J, N'Dure F, Liu S, Badwan R, Branco F, Hood-Humphrey V, Franchimont N, Hanna J, Maghzi AH. Effect of Dimethyl Fumarate vs Interferon beta-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical Trial. JAMA Netw Open. 2022 Sep 1;5(9):e2230439. doi: 10.1001/jamanetworkopen.2022.30439. PubMed 36169959 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in Jul 2025, 130 months.

Results were first posted in May 2026, 10 months after primary completion.

Of 28 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 130 months is above that.

Counting every sponsor, half of 38 studies reached it within 48 months; a quarter within 27 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2014
First posted
Nov 5, 2014
StartActual
Aug 28, 2014
Primary completionActual
Jul 8, 2025
CompletionActual
Jul 8, 2025
Results first posted
May 19, 2026
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02283853
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Nov 5, 2014
Start date
Aug 28, 2014
Primary completion
Jul 8, 2025
Completion
Jul 8, 2025
Results posted
May 19, 2026
Last update
May 19, 2026

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion